EVMMClinical Trials•prnewswire•September 2, 2025 at 01:30 PM

Evommune Announces Late-Breaker Presentation of Phase 2 Data for EVO756 in Chronic Inducible Urticaria at Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

Sentiment:Positive (65)

Summary

(EVMM) --Company to host a webcast to review the full data set from Phase 2 trial -- PALO ALTO, Calif., Sept. 2, 2025 /PRNewswire/ -- Evommune, Inc., a clinical stage biotechnology company discovering and developing innovative therapies that target key drivers of chronic inflammatory diseases,...

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on September 2, 2025 by prnewswire